SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...
Please provide your email address to receive an email when new articles are posted on . Tolebrutinib was associated with a 31% reduced risk for 6-month confirmed disability progression vs. placebo.
Findings showed the study met its primary endpoint demonstrating a reduction in disability accumulation with tolebrutinib compared with placebo. Tolebrutinib was found to delay disability progression ...
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS).
RMAT designation is based on promising Phase 2 clinical data demonstrating NG01’s potential to reduce disability and ...
Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple sclerosis ...
The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS). The HERCULES ...
Ongoing discussions with the FDA regarding nrSPMS application have indicated regulatory decision for tolebrutinib is anticipated to be delayed In response to an FDA request, Sanofi has submitted an ...
Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's tyrosine ...
A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...
Living with a chronic, progressive condition such as secondary progressive multiple sclerosis (SPMS) can affect both your physical and mental health. SPMS results in a gradual decline in function over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results